A Study of the Efficacy and Safety of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

  • STATUS
    Not Recruiting
  • End date
    Apr 3, 2023
  • participants needed
    375
  • sponsor
    Merck Sharp & Dohme LLC
Updated on 8 August 2022
cardiovascular disease
hypercholesterolemia
lipid-lowering therapy
cholesterol level
lipoprotein cholesterol
cholesterol measurement
pcsk9

Summary

The purpose of this study is to evaluate the efficacy and safety of MK-0616, an oral PCSK9 inhibitor, in lowering low-density lipoprotein cholesterol (LDL-C) in participants with hypercholesterolemia. The primary hypothesis is that at least one of the four doses of MK-0616 tested in this study is superior to placebo on percent change from baseline in LDL-C at Week 8.

Details
Condition Hypercholesterolemia, Familial Hypercholesterolemia
Treatment Placebo, MK-0616
Clinical Study IdentifierNCT05261126
SponsorMerck Sharp & Dohme LLC
Last Modified on8 August 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note